Home > Gastroenterology > Reassuring data on immune checkpoint inhibitors in autoimmune disease

Reassuring data on immune checkpoint inhibitors in autoimmune disease

Journal
Annals of Internal Medicine
Reuters Health - 17/02/2021 - Patients with preexisting autoimmune disease (AIDs) are not at increased risk for immune-related adverse events from immune checkpoint inhibitor (ICI) therapy, although these adverse events may be more likely in patients with inflammatory bowel disease (IBD), new research indicates. "Therefore, we encourage physicians not to withhold ICI in most common AIDs. However, close monitoring in patients with IBD is advised because the incidence of severe colitis and early discontinuation of treatment due to toxicity was higher in this group," Dr. Ellen Kapiteijn with Leiden University Medical Center, the Netherlands, and colleagues advise in Annals of Internal Medicine. Because ICIs can cause immune-related adverse events (irAEs) mimicking immunologic diseases, patients with preexisting AIDs were excluded from clinical trials, they explain. The researchers evaluated the safety and efficacy of ICI therapy in patients with advanced melanom...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on